Related Experiment Video

Updated: Jan 3, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K

Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?

Ainhoa Madariaga1, Pamela J Goodwin2,3, Amit M Oza4,5

  • 1Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 28, 2019
PubMed

Insights

Metformin, a common type 2 diabetes drug, shows potential anticancer effects in gynecologic cancers. Ongoing research explores its use in cancer prevention and as a treatment enhancer.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Metformin is a widely used, cost-effective medication for type 2 diabetes.
  • Emerging evidence suggests metformin possesses anticancer properties relevant to gynecologic malignancies.

Purpose of the Study:

  • To explore the potential anticancer effects of metformin in gynecologic cancers.
  • To review metformin's mechanisms of action and current research in cancer prevention and treatment enhancement.

Main Methods:

  • Review of existing literature and ongoing studies on metformin's role in gynecologic oncology.
  • Analysis of metformin's molecular targets, including the PI3K-mTOR pathway and hormone receptors.
  • Assessment of metformin's impact on tumor microenvironment factors like fibrosis and inflammation.

Main Results:

  • Metformin may inhibit the PI3K-mTOR pathway, a key signaling cascade in cancer.
  • Potential for metformin to modulate hormone receptor activity relevant to gynecologic cancers.
  • Evidence suggests metformin can reduce fibrosis and inflammation, potentially creating an less conducive tumor microenvironment.

Conclusions:

  • Metformin demonstrates promising anticancer potential in gynecologic malignancies through multiple biological pathways.
  • Further clinical studies are warranted to establish metformin's efficacy in cancer prevention and as an adjunct cancer therapy.
  • Metformin represents a potential therapeutic agent for gynecologic cancers, leveraging its established safety profile.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.1K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.8K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
543
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
482
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
521
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K